Exchange: NASDAQ·Updated 04:26 AM EDT
REPL logo

REPL Replimune Group Inc

$15.98
$0.1021
(0.64%)
Pre-Market
Prev Close $15.88
Reported EarningsAug 14
Mkt Cap$1.49B
Vol35.00

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
57

Bullish Sentiment

How do you feel about REPL?

Advertisement|Remove ads.